|
Sign In to gain access to subscriptions and/or personal tools.
|
Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes
J Chapman
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv 69978, Israel.
M Cohen-Armon
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv 69978, Tel Hashomer, Israel
Y Shoenfeld
Department of Medicine B and Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel Hashomer, Israel
A D Korczyn
Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv 69978, Tel Hashomer, Israel
Antiphospholipid antibodies (aPL) are associated with neurological diseases such as stroke, migraine, epilepsy and dementia and are thus associated with both vascular and non-vascular neurological disease. We have therefore examined the possibility that these antibodies interact directly with neuronal tissue by studying the electrophysiological effects of aPL on a brain synaptosoneurosome preparation. IgG from patients with high levels of aPL and neurological involvement was purified by protein-G affinity chromatography as was control IgG pooled from ten sera with low levels of aPL. Synaptoneurosomes were purified from perfused rat brain stem. IgG from the patient with the highest level of aPL at a concentration equivalent to 1:5 serum dilution caused significant depolarization of the synaptoneurosomes as determined by accumulation of the lipophylic cation [3H]-tetraphenylphosphonium. IgG from this patient as well as IgG from two elderly patients with high levels of aPL were subsequently shown to permeabilize the synaptosomes to labeled nicotinamide adenine dinucleotide (NAD) and pertussis toxin-ADP-ribose transferase (PTX-A protein) as assayed by labeled ADP-ribosylation of G-proteins in the membranes. No such effects were seen with the control IgG. aPL may thus have the potential to disrupt neuronal function by direct action on nerve terminals. These results may explain some of the non-thromboembolic CNS manifestations of the antiphospholipid syndrome.
Key Words: antiphospholipid antibodies • antiphospholipid syndrome • ß2-glycoprotein 1 (apolipoprotein H) • rat brain • synaptoneurosomes
Lupus, Vol. 8, No. 2,
127-133 (1999)
DOI: 10.1191/096120399678847524
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
R M Andrade, G S Alarcon, L A Gonzalez, M Fernandez, M Apte, L M Vila, G McGwin Jr, J D Reveille, and for the LUMINA Study Group
Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV)
Ann Rheum Dis,
June 1, 2008;
67(6):
829 - 834.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Zandman-Goddard, Y Berkun, O Barzilai, M Boaz, M Ram, J. Anaya, and Y Shoenfeld
Neuropsychiatric lupus and infectious triggers
Lupus,
May 1, 2008;
17(5):
380 - 384.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y. Shoenfeld, P. L. Meroni, and R. Cervera
Antiphospholipid syndrome dilemmas still to be solved: 2008 status
Ann Rheum Dis,
April 1, 2008;
67(4):
438 - 442.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R Cimaz, P L Meroni, and Y Shoenfeld
Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome)
Lupus,
April 1, 2006;
15(4):
191 - 197.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D Paran, J Chapman, A D Korczyn, O Elkayam, O Hilkevich, G B Groozman, D Levartovsky, I Litinsky, D Caspi, Y Segev, et al.
Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis
Ann Rheum Dis,
April 1, 2006;
65(4):
525 - 528.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I Krause, S Lev, A Fraser, M Blank, M Lorber, L Stojanovich, J Rovensky, J Chapman, and Y Shoenfeld
Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome
Ann Rheum Dis,
October 1, 2005;
64(10):
1490 - 1493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A T Rowshani, P Remans, A Rozemuller, and P P Tak
Cerebral vasculitis as a primary manifestation of systemic lupus erythematosus
Ann Rheum Dis,
May 1, 2005;
64(5):
784 - 786.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Appenzeller, F. Cendes, and L. T.L. Costallat
Epileptic seizures in systemic lupus erythematosus
Neurology,
November 23, 2004;
63(10):
1808 - 1812.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Katzav, J Chapman, and Y Shoenfeld
CNS dysfunction in the antiphospholipid syndrome
Lupus,
December 1, 2003;
12(12):
903 - 907.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P L Meroni, A Tincani, N Sepp, E Raschi, C Testoni, E Corsini, I Cavazzana, S Pellegrini, and A Salmaggi
Endothelium and the brain in CNS lupus
Lupus,
December 1, 2003;
12(12):
919 - 928.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Chapman, J H Rand, R L Brey, S R Levine, I Blatt, M A Khamashta, and Y Shoenfeld
Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies
Lupus,
July 1, 2003;
12(7):
514 - 517.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Y Shoenfeld, A Nahum, A D Korczyn, M Dano, R Rabinowitz, O Beilin, C G Pick, L Leider-Trejo, L Kalashnikova, M Blank, et al.
Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer
Lupus,
June 1, 2003;
12(6):
436 - 442.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S Shrot, A Katzav, A D Korczyn, Y Litvinjuk, R Hershenson, C G Pick, M Blank, J Zaech, Y Shoenfeld, P Sirota, et al.
Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies
Lupus,
November 1, 2002;
11(11):
736 - 743.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E Svenungsson, M Andersson, L Brundin, R van Vollenhoven, M Khademi, A Tarkowski, D Greitz, M Dahlstrom, I Lundberg, L Klareskog, et al.
Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus
Ann Rheum Dis,
April 1, 2001;
60(4):
372 - 379.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
